Digital Noema Telehealth and Lumeon Partner to Optimize Telemedicine Pathways - Gilde Healthcare

Digital Noema Telehealth and Lumeon Partner to Optimize Telemedicine Pathways

February 20, 2017

LONDON AND NEW YORK – Today at HIMSS, Lumeon, a leading digital health company, and Digital Noema Telehealth (DN Telehealth), a provider of telemedicine and remote patient monitoring, announce they are partnering to optimize care pathways for telemedicine reimbursements.

DN Telehealth maximizes collaboration compatibility for its clients and their patients, in real-time, extending consultations beyond a physical clinical setting to include fully secure, web browser-based conferencing sessions.  The solution allows clinicians, caregivers and patients to extend care coordination to go beyond traditional care models, to optimize care and promote patient engagement of any “at risk” patient population, in a fully HIPAA-compliant environment.

Lumeon’s Care Pathway Manager seamlessly integrates clinical and administrative systems, and gives providers the ability to design and automate their own pathway rules, so that each patient is automatically progressed through their personal care journey based on their individual data.

“We’ve been looking for a care pathway automation partner for quite some time,” said Roque Espinal-Valdez, founder, and CEO of DN Telehealth. “With Lumeon’s functionality to automate and orchestrate the care pathway, previously manual tasks are eliminated and we can ensure that reimbursable elements are consistently used to deliver predictable outcomes for our customers in the managed care market.”

“Working with DN Telehealth provides us with the opportunity to address one of the fastest growing sectors within healthcare,” said Robbie Hughes, Lumeon CEO. “At the same time, our platform will enable customers of DN Telehealth to automate and orchestrate their care pathways to maximize reimbursement and improve efficiency of care delivery.”

The solution is available in North American and European markets from March 2017.

Gilde Healthcare raises €600 million to invest in healthcare innovation

A balanced mix of international investors commits €600 million to Gilde Healthcare Venture&Growth VI, a transatlantic investment fund Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by its...
April 19, 2023

Gilde Healthcare portfolio company Moximed obtains FDA Market Authorization of the MISHA™ Knee System for People Suffering from Knee Osteoarthritis

Implantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement MISHA Knee System is implanted during an outpatient procedure; it's the first and only device of...
April 13, 2023

Gilde Healthcare company Adcendo announces extension of series A financing to EUR 82M to develop its first-in-class ADC pipeline

Gilde Healthcare portfolio company Adcendo Aps (‘Adcendo’), focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces the successful completion of a Series...
April 4, 2023